We could not analyze the effect of human epidermal growth factor receptor 2 (HER2) status on the risk of upstaging to invasive disease as it is not routine practice at our institution to test for HER2 receptor status in patients with DCIS. Here, ERBB2 is linked to ductal breast carcinoma in situ.